0.8632
5.14%
-0.0468
시간 외 거래:
.87
0.0068
+0.79%
전일 마감가:
$0.91
열려 있는:
$0.94
하루 거래량:
1.79M
Relative Volume:
2.27
시가총액:
$68.66M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-1.0276
EPS:
-0.84
순현금흐름:
$-56.88M
1주 성능:
-17.00%
1개월 성능:
-26.85%
6개월 성능:
-54.33%
1년 성능:
-34.61%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
CTMX | 0.8632 | 68.66M | 101.21M | -569.00K | -56.88M | -0.84 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
2022-06-24 | 개시 | BMO Capital Markets | Outperform |
2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
2021-11-15 | 개시 | BTIG Research | Buy |
2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2021-03-29 | 개시 | JP Morgan | Overweight |
2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
2020-05-14 | 재확인 | H.C. Wainwright | Buy |
2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
2020-03-04 | 개시 | Barclays | Equal Weight |
2019-11-20 | 개시 | Guggenheim | Buy |
2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-06-13 | 개시 | Mizuho | Buy |
2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
2019-03-11 | 개시 | Barclays | Overweight |
2018-11-26 | 개시 | Piper Jaffray | Overweight |
2018-10-15 | 개시 | Goldman | Neutral |
2018-09-13 | 개시 | H.C. Wainwright | Buy |
2018-06-01 | 개시 | SunTrust | Buy |
2018-01-05 | 개시 | Citigroup | Buy |
2017-09-08 | 개시 | Wedbush | Outperform |
2017-03-27 | 개시 | H.C. Wainwright | Buy |
2017-03-02 | 개시 | Instinet | Buy |
2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com Canada
TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com
Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com
HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World
HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat
CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK
CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times
CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks
CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St
CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat
CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily
Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex
CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World
Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News
Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com
CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily
Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News
Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News
Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex
Altamira Therapeutics Reports Narrowed Losses - TipRanks
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan
This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat
Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat
Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytomx Therapeutics Inc 주식 (CTMX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
자본화:
|
볼륨(24시간):